Results 81 to 90 of about 35,228 (288)

Deciphering transcriptional plasticity in pancreatic ductal adenocarcinoma reveals alterations in sensory neuron innervation

open access: yesMolecular Oncology, EarlyView.
Pancreatic sensory neurons innervating healthy and PDAC tissue were retrogradely labeled and profiled by single‐cell RNA sequencing. Tumor‐associated innervation showed a dominant neurofilament‐positive subtype, altered mitochondrial gene signatures, and reduced non‐peptidergic neurons.
Elena Genova   +14 more
wiley   +1 more source

Methods and applications of patient-derived organoid models for immune microenvironment and immunotherapy research in multiple cancer types

open access: yesExperimental Hematology & Oncology
Lack of pre-clinical models that simulate the complex TME and translate to human immunity is list as the top one challenge in the area of cancer immunotherapy development.
Yaya Yu   +9 more
doaj   +1 more source

Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models

open access: yesBMC Cancer, 2018
Background Patient-derived tumor models are the new standard for pre-clinical drug testing and biomarker discovery. However, the emerging technology of primary pancreatic cancer organoids has not yet been broadly implemented in research, and complex ...
Susan Tsai   +10 more
doaj   +1 more source

Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss [PDF]

open access: yes, 2015
Genome-wide analyses have identified thousands of long noncoding RNAs (lncRNAs). Malat1 (metastasis-associated lung adenocarcinoma transcript 1) is among the most abundant lncRNAs whose expression is altered in numerous cancers.
Akerman, M.   +12 more
core   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata   +10 more
wiley   +1 more source

The use of organoids in creating immune microenvironments and treating gynecological tumors

open access: yesJournal of Translational Medicine
Owing to patient-derived tumor tissues and cells, significant advances have been made in personalized cancer treatment and precision medicine, with cancer stem cell-derived three-dimensional tumor organoids serving as crucial in vitro models that ...
Ling-Feng Zhou   +3 more
doaj   +1 more source

Low-viscosity Matrix Suspension Culture for Human Colorectal Epithelial Organoids and Tumoroids

open access: yesBio-Protocol, 2022
Three-dimensional culture of human normal colorectal epithelium and cancer tissue as organoids and tumoroids has transformed the study of diseases of the large intestine.
Tao Tan   +4 more
doaj   +1 more source

Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer [PDF]

open access: yes, 2017
Pancreatic stellate cells (PSCs) differentiate into cancer-associated fibroblasts (CAFs) that produce desmoplastic stroma, thereby modulating disease progression and therapeutic response in pancreatic ductal adenocarcinoma (PDA).
Abram Handly-Santana   +79 more
core   +2 more sources

Combined 5‐aminolevulinic acid and ferric ammonium citrate treatment promotes hair follicle growth by activating dermal papilla cells

open access: yesFEBS Open Bio, EarlyView.
5‐Aminolevulinic acid combined with ferric ammonium citrate (5‐ALA/FAC) stimulates dermal papilla cell activity and promotes hair follicle growth. The treatment enhances ERK and AKT signaling, increases hair‐inductive gene expression, and restores dermal papilla function suppressed by dihydrotestosterone and oxidative stress, resulting in enhanced hair
Han‐Wook Ryu, Eok‐Soo Oh, Sewoon Kim
wiley   +1 more source

Plocabulin Displays Strong Cytotoxic Activity in a Personalized Colon Cancer Patient-Derived 3D Organoid Assay

open access: yesMarine Drugs, 2019
Plocabulin is a novel microtubule-disrupting antitumor agent of marine origin that is currently undergoing phase II clinical trials. Plocabulin has potent antiproliferative and antiangiogenic actions in carcinoma cell lines and has antitumor activity in ...
Alba Costales-Carrera   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy